Fresenius SE Company Profile (NASDAQ:FSNUY)

About Fresenius SE (NASDAQ:FSNUY)

Fresenius SE logoFresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure. This segment offers dialyzers, dialysis machines, and renal pharmaceuticals, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs comprising intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing whole blood and blood components, as well as in transfusion medicine. The Fresenius Helios segment operates approximately 112 hospitals, including 88 acute care hospitals and 24 post-acute care clinics; 78 outpatient clinics; 4 out-patient post-acute care centers; 18 prevention centers; and 13 nursing homes. This segment has approximately 35,000 beds. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as provides maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg, Germany.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FSNUY
  • CUSIP: N/A
  • Web:
Average Prices:
  • 52 Week Range: $17.22 - $22.30
  • Trailing P/E Ratio: 22.16
  • Foreward P/E Ratio: 5.05
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $37.35 billion
  • Price / Sales: N/A
  • Book Value: $6.94 per share
  • Price / Book: 3.00
  • Dividend Yield: 0.6%
  • EBIDTA: $6.97 billion

Frequently Asked Questions for Fresenius SE (NASDAQ:FSNUY)

What is Fresenius SE's stock symbol?

Fresenius SE trades on the NASDAQ under the ticker symbol "FSNUY."

How often does Fresenius SE pay dividends? What is the dividend yield for Fresenius SE?

Fresenius SE declared a None dividend on Thursday, June 29th. Shareholders of record on Wednesday, May 17th will be paid a dividend of $0.112 per share on Wednesday, May 24th. The ex-dividend date is Monday, May 15th. View Fresenius SE's Dividend History.

When will Fresenius SE make its next earnings announcement?

Fresenius SE is scheduled to release their next quarterly earnings announcement on Friday, August, 25th 2017. View Earnings Estimates for Fresenius SE.

Who are some of Fresenius SE's key competitors?

How do I buy Fresenius SE stock?

Shares of Fresenius SE can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fresenius SE's stock price today?

One share of Fresenius SE stock can currently be purchased for approximately $20.79.

MarketBeat Community Rating for Fresenius SE (NASDAQ FSNUY)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Fresenius SE and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Fresenius SE (NASDAQ:FSNUY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Fresenius SE (NASDAQ:FSNUY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/11/2016Sanford C. BernsteinInitiated CoverageOutperformN/AView Rating Details
3/17/2016NomuraInitiated CoverageNeutralN/AView Rating Details
2/12/2016Berenberg BankUpgradeHold -> BuyN/AView Rating Details
(Data available from 8/23/2015 forward)


Earnings History for Fresenius SE (NASDAQ:FSNUY)
No earnings announcements for this company have been tracked by


Earnings Estimates for Fresenius SE (NASDAQ:FSNUY)
Current Year EPS Consensus Estimate: $3.69 EPS
Next Year EPS Consensus Estimate: $4.12 EPS


Dividend History by Quarter for Fresenius SE (NASDAQ FSNUY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Fresenius SE (NASDAQ:FSNUY)
No insider trades for this company have been tracked by


Headline Trends for Fresenius SE (NASDAQ:FSNUY)
Latest Headlines for Fresenius SE (NASDAQ:FSNUY)
DateHeadline logoZacks: Fresenius SE (NASDAQ:FSNUY) Receives Consensus Recommendation of "Hold" from Brokerages - August 13 at 10:40 AM logoFresenius SE (FSNUY) Lifted to Strong-Buy at Zacks Investment Research - August 5 at 12:40 AM logoZacks: Fresenius SE (NASDAQ:FSNUY) Receives Consensus Rating of "Hold" from Analysts - August 4 at 8:08 AM logoFresenius' (FSNUY) CEO Stephan Sturm on Q2 2017 Results - Earnings Call Transcript - August 2 at 12:28 AM logoZacks: Fresenius SE (NASDAQ:FSNUY) Given Average Rating of "Hold" by Brokerages - July 19 at 12:38 PM logo Fresenius SE (FSNUY) Receives Consensus Recommendation of "Hold" from Analysts - July 11 at 4:52 PM logoFresenius SE (FSNUY) Stock Rating Upgraded by Zacks Investment Research - June 21 at 10:02 PM logoZacks: Fresenius SE (FSNUY) Given Average Recommendation of "Hold" by Brokerages - June 14 at 4:46 PM logo3 Strong Buy Non-U.S. Mutual Funds For Best Returns - June 7 at 11:52 PM logoZacks: Fresenius SE (FSNUY) Receives Average Recommendation of "Hold" from Analysts - May 26 at 8:44 PM logoFresenius SE & Co. KGaA's (FSNUY) Management on Q1 2017 Results - Earnings Call Transcript - May 7 at 10:13 AM logoZacks: Fresenius SE (FSNUY) Given Consensus Rating of "Hold" by Brokerages - May 4 at 6:34 PM logoFresenius Spends Billions On a Falling Akorn - April 25 at 11:18 AM logoDrugmaker asked Arkansas not to use drug in executions - April 21 at 11:39 AM logo Fresenius SE (FSNUY) Given Consensus Recommendation of "Hold" by Analysts - April 17 at 6:36 PM logo2 firms seek to prevent drugs' use in Arkansas executions - April 13 at 10:13 PM logoCould This Small Biotech Get Taken Over By Germany's Fresenius? - April 10 at 11:29 AM logo[$$] Fresenius in Talks to Buy U.S. Drug Maker Akorn - April 8 at 9:39 AM logo Fresenius SE (FSNUY) Receives Consensus Recommendation of "" from Analysts - March 28 at 11:25 AM



Fresenius SE (FSNUY) Chart for Wednesday, August, 23, 2017

This page was last updated on 8/23/2017 by Staff